Key Features are
- Novel, potent and selective muscarinic M1 positive allosteric modulator (M1 PAM) with no agonist like activity
- Selective against muscarinic subtypes M2 to M5 (both orthosteric as well as allosteric site)
- Excellent ADME properties with no drug-drug interaction liability
- Good brain penetration and high CSF concentrations in rats
- Robust efficacy in preclinical animal models of cognition
- Potentiates the preclinical efficacy of current SOC for AD treatment (EEG)
- Dose dependent increase in the cortical sAPPα levels
- No Cholinergic effects like salivation, emesis or diarrhea in Beagle Dogs
- Excellent margin of safety in 7-day rat toxicity study
- Well protected intellectual property in all major market
GLP toxicity studies is in planning
